Lymphoma
Conditions
Keywords
recurrent adult Hodgkin lymphoma, recurrent/refractory childhood Hodgkin lymphoma
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy using cyclosporine, interferon gamma, and interleukin-2 after stem cell transplantation may help the transplanted cells make an immune response and kill any remaining cancer cells. It is not yet known whether high-dose chemotherapy followed by autologous stem cell transplantation is more effective with or without immunotherapy. PURPOSE: This randomized phase II/III trial is studying how well high-dose chemotherapy followed by autologous stem cell transplantation, cyclosporine, interferon gamma, and interleukin-2 works and compares it to high-dose chemotherapy followed by autologous stem cell transplantation only in treating patients with refractory or relapsed Hodgkin's lymphoma.
Detailed description
OBJECTIVES: Primary * Phase II * Determine the feasibility and toxicity of immunotherapy comprising cyclosporine, interferon gamma, and interleukin-2 after high-dose myeloablative chemotherapy with autologous stem cell transplantation (ASCT) in patients with refractory or relapsed Hodgkin's lymphoma. * Phase II part of the study was completed and should have proceeded to Phase III; however long delay occurred due to some proposed protocol changes to Phase III , so long that the study got permanently closed \*\*\*\*\*\*\*\*\*\*\* * Phase III * Compare the event-free and overall survival of patients treated with vs without this immunotherapy regimen. Secondary * Determine the event-free and overall survival rates, toxic effects, and response rates to reinduction chemotherapy followed by hyperfractionated involved-field radiotherapy, high-dose chemotherapy comprising carmustine, etoposide, cytarabine, and melphalan, and ASCT in these patients. * Correlate tumor biologic characteristics with response in patients treated with these regimens. * Determine the effectiveness of this immunotherapy regimen in producing autologous graft-vs-host disease (GVHD) and auto-reactive cytotoxic T-lymphocyte activity in these patients. * Correlate greater levels of autologous GVHD and in vitro cytolytic activity with improved event-free and overall survival in patients treated with these regimens. * Determine whether treatment with immunotherapy can overcome the negative prognostic significance of p53 mutation and high serum levels of interleukin-10 and interleukin-2 receptor in these patients. * Determine the genotoxicity of retrieval therapy and the incidence of hypermutability by longitudinal genotoxic biomonitoring in these patients. * Correlate HLA class II invariant peptide (CLIP) expression in tumor cells with improved event-free and overall survival in patients treated with immunotherapy regimen. OUTLINE: This is a nonrandomized, multicenter phase II study followed by a randomized, multicenter phase III study. Patients are stratified according to study phase (II vs III). Patients receive 2 courses of salvage induction therapy on COG-AHOD00P1 or equivalent. Within 2-5 weeks after completion of salvage induction therapy, patients receive protocol therapy. * Phase II: All patients receive the following treatment: * Hyperfractionated involved-field radiotherapy: Patients who have completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days. * High-dose preparative regimen: Beginning within 7 days after radiotherapy, patients receive carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1. * Autologous stem cell transplantation: Patients undergo autologous bone marrow or peripheral blood stem cell transplantation on day 0. Patients then receive filgrastim (G-CSF) subcutaneously (SC) or IV beginning on day 1 and continuing until blood counts recover. * Immunotherapy: Patients receive cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of interferon gamma and interleukin-2. When sufficiently recovered, patients also receive interferon gamma SC every other day for 10 doses. Beginning 2 days after the start of interferon gamma, patients also receive interleukin-2 SC once daily for 18 days. * Phase III: Patients who respond to prior salvage induction therapy are randomized to 1 of 2 treatment arms. Patients who have progressive disease after 2 courses of prior salvage induction therapy are assigned to arm I. * Arm I: Patients receive treatment as in phase II. * Arm II: Patients receive treatment as in phase II without immunotherapy. In both phases, treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 year. PROJECTED ACCRUAL: A total of 156 patients (25 for phase II and 131 for phase III) will be accrued for this study within 5.4 years.
Interventions
BIOLOGICALaldesleukin
Given IV
BIOLOGICALfilgrastim
Given IV
BIOLOGICALrecombinant interferon gamma
Given IV
DRUGcarmustine
Given IV
DRUGcyclosporine
Given IV
DRUGcytarabine
Given IV
DRUGetoposide
Given IV
DRUGmelphalan
Given IV
PROCEDUREautologous bone marrow transplantation
PROCEDUREbone marrow ablation with stem cell support
PROCEDUREperipheral blood stem cell transplantation
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 30 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of Hodgkin's lymphoma * Histologically confirmed at original diagnosis AND at relapse or disease progression * Relapsed or refractory to conventional therapy * No recurrence without B symptoms or bulky disease at least 1 year after completion of minimal systemic therapy defined by either of the following: * Stage IA/IIA with nodal disease previously treated with radiotherapy only * Stage IA/IIA with nodal disease previously treated with less than 3 courses of standard dose chemotherapy * Concurrently enrolled on the COG-AHOD00P1 salvage chemotherapy study OR received other appropriate salvage therapy (e.g., ifosfamide and vinorelbine) PATIENT CHARACTERISTICS: Age * Under 30 Performance status * ECOG 0-2 (for adults) * Lansky 50-100% (for children) Life expectancy * At least 2 months Hematopoietic * Absolute neutrophil count at least 500/mm\^3 Hepatic * Bilirubin no greater than 1.5 times normal * SGPT less than 2.5 times normal Renal * Creatinine no greater than 1.5 times normal OR * Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min/1.73 m\^2 Cardiovascular * Shortening fraction at least 27% by echocardiogram OR * Ejection fraction at least 50% by MUGA Pulmonary * No evidence of dyspnea at rest * No exercise intolerance * DLCO at least 50% (patients 8 years of age and over) Other * Not pregnant or nursing * Negative pregnancy test * No concurrent serious illness PRIOR CONCURRENT THERAPY: Biologic therapy * Recovered from prior immunotherapy * At least 1 week since prior antineoplastic biologic agents * More than 1 week since prior growth factors * No prior stem cell transplantation * No other concurrent immunomodulating agents Chemotherapy * See Disease Characteristics * More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered * No other concurrent anticancer chemotherapy Endocrine therapy * No concurrent steroids, including dexamethasone as an antiemetic Radiotherapy * See Disease Characteristics * Recovered from prior radiotherapy Surgery * Not specified Other * No concurrent participation in another COG therapeutic study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of death, excluding death due to disease, during the period of time from day 0 (transplant) through day 100 post transplant | Day 0 (transplant) through Day 100 (Post transplant) | Death, excluding death due to disease, during the period of time from Day 0 (transplant) through Day 100 post transplant. |
Countries
Australia, Canada, United States
Outcome results
None listed